GlaxoSmithKline's investigational Lp-PLA 2 inhibitor darapladib has failed in a second Phase III study, SOLID-TIMI 52, all but extinguishing any hopes for the product.
Top-line results show that the 13,000-patient trial missed its primary endpoint of a reduction of major coronary events, versus placebo...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?